The development of in vitro diagnostic (IVD) products must adhere to strict medical device quality management systems. This article integrates regulatory requirements from authorities such as the NMPA and FDA to systematically analyze the four core stages of IVD development. It highlights key technical control points across the entire development cycle, including demand definition and concept verification, design development and process confirmation, clinical evaluation and system verification, as well as registration application and life cycle management.
Demand Definition and Concept Verification
Foundation of R&D: Transforming clinical needs into viable projects is the cornerstone of IVD product development. Companies must accurately identify unmet clinical demands through hospital visits, bibliometric analysis, and other research methods. Establishing a comprehensive demand matrix-including clinical performance, ease of operation, and cost considerations-is essential for guiding product development.
Design Development and Process Confirmation
Transition to Industrialization: This phase focuses on refining laboratory processes for large-scale manufacturing while ensuring compliance with ISO 13485 standards. Key technical controls include:
Analytical Performance Optimization: Enhancing reaction systems using orthogonal experimental designs, such as optimizing primer concentration in PCR kits (typically tested across ≥5 concentration points).
Design Freeze Management: Finalizing technical parameters after three rounds of design reviews. Any subsequent modifications require initiating the CAPA (Corrective and Preventive Action) process.
Process Verification: Key process parameters (CPP) must be validated through DOE (Design of Experiments). For instance, freeze-drying programs must confirm critical factors such as heating rate (±0.5℃/min) and residual moisture levels (≤3%).
Clinical Evaluation and System Verification
Building a Robust Evidence Chain: Following the "Technical Guidelines for Clinical Trials of In Vitro Diagnostic Reagents," companies must ensure:
Comparative Studies: Evaluating new products against similar market alternatives with sufficient statistical power (typically requiring ≥100 positive samples).
Interference Testing: Assessing the effects of over 50 potential interfering substances.
Stability Studies: Real-time stability data should cover the claimed shelf life (e.g., 24 months). Transportation validation should simulate extreme conditions such as vibration (≥3G) and temperature variations (-20℃ to 37℃ cycles).
Registration Application and Life Cycle Management
Ensuring Regulatory Compliance: The registration dossier must include a complete "Design History File (DHF)," with particular emphasis on:
Risk Analysis Reports: Conducting FMEA (Failure Mode and Effects Analysis) covering ≥30 failure modes.
Biosafety Evaluations: Ensuring compliance with GB/T 16886 series standards.
Clinical Data Analysis: Employing robust statistical methods, such as ensuring Kappa values ≥0.75 and ROC curve AUC >0.85.
Post-Market Supervision: Implementing a Post-Market Clinical Follow-up (PMCF) plan to continuously monitor product performance through LIS (Laboratory Information System) data analysis, conducting annual trend evaluations, and updating risk management documentation.
Conclusion
IVD research and development is a highly structured process that requires a robust management system incorporating Quality by Design (QbD) principles. With advancements in AI-assisted diagnostics and microfluidic technology, R&D timelines have been reduced from the traditional 36 months to approximately 18–24 months. However, maintaining compliance and ensuring product quality remain the fundamental pillars of success in the IVD industry.